الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
Hepatic fibrosis is commonly preceded by CLD and result from the progressive accumulation and decreased degradation or remodeling of the extracellular matrix (ECM), any etiology, including viral infection, alcoholic liver disease and non-alcoholic steatohepatitis. Liver cirrhosis is a frequent consequence of the long clinical course of all chronic liver diseases and is characterized by tissue fibrosis and the conversion of normal liver architecture into structurally abnormal nodules.
MicroRNAs (miRNA or miR) are short, 18 to 25 nucleotide long, non-coding, single-stranded RNA that function as regulatory molecules and said to involve in a series of vital processes including cell growth and differentiation, apoptosis, metabolism, and the pathogenesis of various human diseases. miR-192 is widely distributed in the kidney, liver, and colon. It is downregulated in tumors such as colon, liver, and lung cancers, thereby serving as a tumor inhibitor.
Our study was a case control study, conducted in Beni-Suef University Hospital on 92 patients between from July 2021 to September 2021. Our study was aiming to assess serum miRNA-192 and its role in the pathophysiology of liver cirrhosis. Participants were divided into four groups: group (1) consisted of 23 healthy controls (Control group), group (2) included 23 patients with (compensated liver cirrhosis), group (3) involved of 23 patients with (uncompensated liver cirrhosis) and group (4) consisted of 23 patients with (cirrhosis with Hepatocellular carcinoma HCC). Approval was asked from institutional review board (IRB).
All patients were subjected to full history taking, routine clinical examination, laboratory investigations and serum microRNA-192 assessment. The results were collected, analyzed, tabulated, and summarized statistically using SPSS software for data processing and statistics.
In our study, we made a comparison of liver functions tests between the four studied groups. ALT and AST, AFP were significantly highest among group (IV) HCC as compared with the other three studied groups and were lowest among healthy control group as compared with the other three groups.
Bilirubin and INR was significantly highest among group (III) (decompensated liver cirrhosis) as compared with the other three studied groups.
Regarding the microRNA192 between the four studied groups, microRNA192 was significantly highest among group (IV) liver cirrhosis with HCC as compared with the other three studied groups and was lowest among healthy control and compensated liver cirrhosis group as compared with uncompensated and HCC groups. There was non-statistically significant difference between groups (I) and (II) regarding microRNA192.
Using ROC curve analysis, the sensitivity and specificity of microRNA192 serum level for prediction of different liver conditions in the current study was evaluated. A microRNA192 serum level of ≥110 could predict uncompensated liver disease with a sensitivity of 60.9% and a specificity of 100%. A microRNA192 serum level of ≥2.55 could predict cirrhotic liver disease with HCC with a sensitivity of 73.9%% and a specificity of 95.7%.